Many patients are burdened by prescription costs, yet it is not clear whether brand-named fixed-dose combination medicines are less expensive than the sum of the cost of their generic components.
Fixed-dose combination therapy, the combination of two or more drugs from different therapeutic classes into a single tablet, represents an important clinical innovation. 1, 2 Because most patients with hypertension will require more than one pharmacologic agent, fixed-dose therapy offers the advantage of simplifying prescription regimens and potentially increasing adherence. 3 This is especially important given that up to one half of medications used to treat hypertension and other chronic diseases are not filled and taken as prescribed. 4 Despite this, fixed-dose combination therapy also comes at a cost; many medicines that are marketed as fixed-dose combinations are available as brand-name drugs alone, and overall the costs of brand-name drugs are considerably greater than drugs that are available as generic equivalents.
We sought to compare the cost of several of the most commonly prescribed brand-named fixed-dose combination medicines used to treat hypertension with the costs of their generic components. We were particularly interested in this question given widespread patient burden from out-of-pocket prescription costs, and given that the use of fixed-dose combination therapy is one way that physicians may try to assist patients burdened by their prescription costs.
METhOdS data
We used the 2004 Medical Expenditure Panel Survey to analyze and compare the relative costs of combination drugs and their individual components. The survey, funded by the Agency of Healthcare Research and Quality, uses a longitudinal panel design and a national probability sample of the noninstitutionalized population to examine individuals' health-care utilization and expenditures. Here, we focus on the household component of the survey that includes information on prescribed medicines. Data on each prescription medicine purchased by a survey participant is derived from self-report and supplemented with analyses of pharmacy and medical records. These records include receipts, bills, and other documentation of payments for a given individuals' medical care (e.g., prescription drugs), including out-of-pocket disbursements and payments made by other sources such as Medicare, Medicaid, or private insurers.
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Records regarding prescription drug utilization were then used to link individual unique prescriptions with national drug codes that provide greater specificity regarding the type and dose of drug dispensed. In the 2004 prescription drug file, 81% of the individual prescription records provided by survey participants could be linked to a particular national drug code through pharmacy records. Analysis of the data to check consistency and sensitivity, including the use of imputation for prescriptions reports that could not be matched to pharmacy records, suggest the validity of the coding process. 5 For our analyses, we first limited our sample to the 18% of all the prescription drug records in 2004 used to treat hypertension. We then further limited our analysis to the most commonly used fixed-dose combination medicines to treat hypertension (e.g., Zestoretic), as well as each drugs' constituent components (e.g., hydrochlorothiazide and lisinopril).
Analysis
For each of the most commonly prescribed fixed-dose combination drugs, we first examined the subject's out-of-pocket costs. Next, we examined the sum of all payments made by other sources such as Medicare, Medicaid, and other public or private sources of payment. We similarly examined the out-of-pocket and third party expenditures associated with each individual 
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component of the combination medicine. In all cases, we summed the out-of-pocket (or third-party) costs of the individual components, and we compared the costs of prescription drugs of the same strength (e.g., Zestoretic 25/20 was compared with the sum of the costs of hydrocholorothiazide 25 mg and lisinopril 20 mg).
Because most fixed-dose combination medicines are dispensed as brand-name single source drugs, and because most of their constituent drugs are available as generics, our main analyses compared the costs of brand-named combination medicines and their generic components. However, we also repeated our analyses examining the average costs of all combination medicines, whether dispensed as branded or generic products, and all of their constituent ingredients, once again whether dispensed as branded or generic products.
In all cases, we examined both absolute and relative difference in costs between drugs. We estimated the arithmetic means along with 95% confidence intervals and number of observations for each drug. We excluded combination drugs that were infrequently prescribed (i.e., <20 observations), because analyses of these drugs would not provide statistically reliable estimates. We also omitted the combination drugs for which cost of individual ingredients was not possible to ascertain because individual components were not observed in Medical Expenditure Panel Survey. This left us with 27 combination drugs with various active ingredients and prescription strength combinations, which accounted for 38% of unique combination antihypertensive drugs prescribed during the study period. We applied full-year person level sample weights included in Medical Expenditure Panel Survey, which allowed for us to account for the complex sampling design of the survey. All analyses were done using Stata version 9.2 (College Station, TX).
RESUlTS
Overall, 14% of all antihypertensive prescriptions were fixeddose combination drugs; these drugs accounted for 19% of total expenditures for antihypertensives and 25% of out-of-pocket expenditures for antihypertensives. Sixty-three percent of these prescriptions were dispensed as brand-name drugs, while the remainder were dispensed as generics. Twenty-three of the 27 commonly prescribed fixed-dose combination antihypertensives were on patent and available only as brand-named drugs. Table 1 describes the comparison of monthly out-of-pocket prescription costs. For 24 out of 27 cases, the cost of a fixed-dose combination medicine was greater than the sum of the costs of its components. The average increase in the monthly costs between the fixed-dose combination and its components was $13.38 (95% confidence interval, $12.27-14.50), reflecting a 41% increase in out-of-pocket costs through the use of a fixed-dose combination drug. The differences in costs varied considerably, ranging from a decreased cost of $1.10 (6%) to an increased cost of $60.41 (83%). Table 2 describes the total monthly prescription expenditures. In contrast to out-of-pocket expenditures, total expenditures were lower with fixed-dose combination medicines for 23 of the 27 drugs examined. For example, the mean decrease in monthly prescription costs was $20.89 (95% confidence interval, $20.10-21.68) with a combination medicine, reflecting a 32% reduction in total monthly prescription costs. The difference in these costs ranged from an increased total cost of $42.19 (39%) to a decreased total cost of $59.14 (121%).
We also repeated the analysis for a sample extending both brand and generic variations for anti-hypertensive drugs. As expected, analyses that included all combination medicines and their constituent ingredients, regardless of patent status, suggested smaller differences between combination medicines and their constituents. On average, the monthly out-of-pocket costs of combination medicines were only 2% greater than its constituent ingredients, with a mean increase of $0.52 (95% confidence interval, $0.16-0.87). Similarly, the corresponding total monthly costs were 14% less for combination medicines than their constituent drugs, with a mean difference $7.97 (95% confidence interval, $7.70-8.25).
dISCUSSION
In this study of the costs of brand-named fixed-dose combination therapy for hypertension, we found that in general, this clinical strategy was associated with greater out-of-pocket costs than a strategy of prescribing two different medicines reflecting the constituent ingredients of the combination therapy. These cost differences were not trivial; the average out-of-pocket cost difference was ~$13.38, or 41% of the cost of the fixed-dose combination therapy, when a fixed-dose combination medicine was dispensed rather than two separate medicines representing its brief communications
Costs of Combination Antihypertensive Drugs constituent generic ingredients. These findings are important because there is widespread patient burden from out-of-pocket costs, antihypertensives are some of the most commonly prescribed prescription drugs, and modest reductions in outof-pocket costs may be quite meaningful for many poor and elderly patients. Our primary analyses compared the cost of brand-name combination medicines with generic constituents, since this most closely replicates the clinical decision faced by patients and their physicians; physicians were much more likely to prescribe brand medicine if they used a combination antihypertensive than a noncombination therapy (68% vs. 38%). However, the cost differences between generic fixed-dose medicines and their counterparts were much smaller, highlighting the degree to which availability of generic substitutes can influence both the out-of-pocket and total costs of commonly prescribed antihypertensives.
Our results demonstrate a common clinical opportunity for patients and providers to consider the costs of medication therapy and possible opportunities to lower these costs, 6 and may also be useful as inputs into economic models such as costeffectiveness analyses of various treatments. Although fixed-dose combination therapy may simplify a treatment regimen, the benefits of such simplification for some patients may be outweighed by the additional costs of treatment. This is especially true given evidence that the number of daily doses (e.g., twice daily vs. once daily) may be a more important determinant of adherence than the number of medications taken at one time. 7, 8 Thus, the benefits of combination therapy may be especially small when switching from a combination medicine to its constituent parts does not constitute a more frequent daily dosing schedule, or when a lower dose of one of the two components may be possible while maintaining blood pressure control.
As with all studies, this analysis had several limitations. Our data do not allow for us to examine other important factors that should be used to inform prescription choice, such as patient adherence, patient preference, and regimen complexity. Little is known about many of these factors and how they should be balanced with the differences in treatment costs such as those that we describe. Also, our analyses were limited to antihypertensive therapy and conducted based on drugs used during 2004. It is possible, although we believe unlikely, that our results would change markedly if more recent data were to be examined. Finally, we do not examine how expenditures for anti-hypertensives compare to or influence other types of health care utilization or expenditures; such analyses, while important, were beyond the scope of this brief report.
A recent comprehensive review concludes that physicians not only have poor knowledge of drug costs, but that they also tend to systematically underestimate the costs of expensive drugs and overestimate the costs of inexpensive drugs. 9 Given how much variation there is in patient preference and ability to pay for prescription drugs, patient-physician communication about these matters is important. This is especially true since our data suggest marked differences may exist for some patients in the costs of their hypertension therapy based on whether the therapy is dispensed as a fixed-dose combination medicine or its component ingredients.
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